Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2007-05-30
2010-06-01
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S204100, C424S215100, C436S063000, C436S064000, C436S174000, C435S004000, C435S005000, C435S007210, C435S007230, C435S325000, C435S363000, C435S366000, C435S372000, C210S780000, C210S781000, C210S782000, C210S788000
Reexamination Certificate
active
07727534
ABSTRACT:
Reovirus can be used to selectively remove ras-mediated neoplastic cells from a cellular composition. It is of particular interest to purge autographs which may contain neoplastic cells with reovirus before transplanting the autographs back into the recipient, thereby reducing the risk of introducing or reintroducing neoplastic cells into the recipient.
REFERENCES:
patent: 4576928 (1986-03-01), Tani et al.
patent: 5514340 (1996-05-01), Lansdrop et al.
patent: 5585096 (1996-12-01), Martuza et al.
patent: 5801029 (1998-09-01), McCormick
patent: 5837512 (1998-11-01), Rabson et al.
patent: 5840502 (1998-11-01), van Vlasselaer
patent: 5861159 (1999-01-01), Pardoll et al.
patent: 6136307 (2000-10-01), Lee et al.
patent: 6475481 (2002-11-01), Talmadge
patent: 6528057 (2003-03-01), Ambrus et al.
patent: 6596268 (2003-07-01), Coffey et al.
patent: 6649157 (2003-11-01), Coffey et al.
patent: 6994858 (2006-02-01), Morris et al.
patent: 7192580 (2007-03-01), Atkins et al.
patent: 7431932 (2008-10-01), Morris et al.
patent: 2002/0006398 (2002-01-01), Morris et al.
patent: 2002/0037543 (2002-03-01), Atkins et al.
patent: 2003/0044384 (2003-03-01), Roberts et al.
patent: 2003/0165465 (2003-09-01), Roberts et al.
patent: 2004/0109878 (2004-06-01), Atkins et al.
patent: 2005/0026289 (2005-02-01), Morris et al.
patent: 2283280 (1999-02-01), None
patent: 0 451 611 (1991-10-01), None
patent: 1 344 819 (2003-09-01), None
patent: WO 94/18992 (1994-09-01), None
patent: WO 94/25627 (1994-11-01), None
patent: WO 99/08692 (1999-02-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO 99/45783 (1999-09-01), None
patent: WO 00/50051 (2000-08-01), None
patent: WO 01/35970 (2001-05-01), None
Adachi et al., “A Midkine Promoter-based Conditionally Replicative Adenovirus for Treatment of Pediatric Solid Tumors and Bone Marrow Tumor Purging”Cancer Research, 61:7882-7888 (2001).
Garcia-Castro et al., “Purging of leukemia-contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo murine experimental model”Gene Therapy, 10:1328-1335 (2003).
Lillo et al., “Efficient and Nontoxic Adenoviral Purging Method for Autologous Transplantation in Breast Cancer Patients”Cancer Research, 62:5013-5018 (2002).
Armstrong, G.D., et al. (1984). Studies on reovirus receptors of L cells: virus binding characteristics and comparison with reovirus receptors of erythrocytes. Virology. 138(1):37-48.
Bashey, A., et al. (1994). Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway. Blood. 83(4):949-957.
Bensinger, W.I. (1998). Should we purge? Bone Marrow Transplant. 21(2):113-115.
Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Res. 49(17):4682-4689.
Chandron, K., and Nibert, M.L. (1998). Protease cleavage of reovirus capsid protein μ1/μ1C is blocked by alkyl sulfate detergents, yielding a new type of infectious subvirion particle. J Virol. 72(1):467-475.
Coffey, M.C., et al. (1998). Reovirus therapy of tumors with activated ras pathway. Science. 282(5392):1332-1334.
Duggan, P.R., et al. (2000). Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplant. 26(12):1299-1304.
Freshney, R.I. (1997). Culture of animal cells: a manual of basic technique, second edition, p. 217.
Gao, J., et al. (1999). Rapid in situ hybridization technique for detecting malignant mouse cell contamination in human xenograft tissue from nude mice and in vitro cultures from such xenografts. Prostate. 39(1):67-70.
Gentsch, J.R., and Pacitti, A.F. (1985). Effect of neuraminidase treatment of cells and effect of soluble glycoproteins on type 3 reovirus attachment to murine L cells. J Virol. 56(2):356-364.
Gulati, S.C., and Acaba, L. (1993). Rationale for purging in autologous stem cell transplantation. J Hematother. 2(4):467-471.
Hirai, M., et al. (1999). Adenovirus p53 Purging for Human Breast Cancer Stem Cell Products. Acta Haematol 101(2):97-105.
Nieto, Y., and Shpall, E.J. (1999). Autologous stem-cell transplantation for solid tumors in adults. Hematol Oncol Clin North Am. 13(5):939-968, vi.
Nordon, R.E., and Schindhelm, K. (1996). Ex vivo manipulation of cell subsets for cell therapies. Artif Organs. 20(5):396-402.
Norman, K.L, and Lee, P.W. (2000). Reovirus as a novel oncolytic agent. J Clin Invest. 105(8):1035-1038.
Paul, R.W., et al. (1989). The α-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus. Virology. 172(1):382-385.
Rausch, O., and Marshall, C.J. (1999). Cooperation of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways during granulocyte colony-stimulating factor-induced hemopoietic cell proliferation. J Biol Chem. 274(7):4096-4105.
Reddy, R.L. (2005). Mobilization and collection of peripheral blood progenitor cells for transplantation. Transfus Apher Sci. 32(1):63-72.
Satoh, T., et al. (1991). Involvement of ras p21 protein in signal-transduction pathways from interleukin 2, interleukin 3, and granulocyte/macrophage colony-stimulating factor, but not from interleukin 4. Proc Natl Acad Sci USA. 88(8):3314-3318.
Seth, P., et al. (1996). Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res. 56(6):1346-1351.
Spyridonidis, A., et al. (1998). Minimal residual disease in autologous hematopoietic harvests from breast cancer patients. Ann Oncol. 9(8):821-826.
Stewart, D.A., et al. (1999). Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant. 23(2):111-117.
Strong, J.E., et al. (1993). Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology. 197(1):405-411.
Strong, J.E., et al. (1998). The molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. EMBO J. 17(12):3351-3362.
Strong, J.E., and Lee, P.W. (1996). The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 70(1):612-616.
Winter, J.N. (1999). High-dose therapy with stem-cell transplantation in the malignant lymphomas. Oncology (Williston Park). 13(12):1635-1645.
Wu, A.G., et al. (1998). Bone marrow purging of neuroblastoma by attenuated multimutated herpes simplex virus. Proceedings of the American Association for Cancer Research Annual 39:605.
Wu, A., et al. (2001). Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation. Cancer Res. 61(7):3009-3015.
Bar-Eli, N., et al., “Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells,” J. Cancer Res. Clin. Oncol. 122(7):409-415 (1996).
Bischoff, J.R., et al., “An adenovirus mutant that replicates selectively in p53-deficient human tumor,” Science 274(5286):373-376 (1996).
Blagosklonny, M.V., and el-Deiry, W.S., “In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug,” Int. J. Cancer 67(3):386-392 (1996).
Chang, H.W., et al., “The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.” Proc. Nat. Acad. Sci. 89(11):4825-4829 (1992).
Chang, H.W. and Jacobs, B.L., “Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA.” Virology 194(2):537-547 (1993).
Chang, H.W., et al., “Rescue of vaccinia virus lacking the E3L gene by mutants of E3L.” J. Virol. 69(10):6605-6608(1995).
Cozzi et al., “Xenotransplantation, where do we stand?”Journal of Nephrology16:S16-S21 (2003).
Duman et al., “Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression”Nephrol. Dial. Transplant. 17:892-6 (2002).
Ezzat
Coffey Matthew C.
Morris Donald
Thompson Bradley G.
Fish & Richardson PC
Harris Alana M
Oncolytics Biotech Inc.
LandOfFree
Reovirus clearance of ras-mediated neoplastic cells from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reovirus clearance of ras-mediated neoplastic cells from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus clearance of ras-mediated neoplastic cells from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183844